The Ocular Hypertension Treatment Study
Intraocular Pressure Lowering Prevents the Development of Glaucoma, but Does That Mean We Should Treat Before the Onset of Disease?
Arch Ophthalmol. 2004;122:376-378.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
We would like to congratulate Kass et al1 and Gordon et al2 for their 2 well-written articles concerning a well-designed and important study. They clearly demonstrate that medical therapy that lowers intraocular pressure (IOP) prevents or retards the development of glaucoma in patients with ocular hypertension. This is noteworthy as it links the development of glaucoma to IOP lowering for the first time in a conclusive manner. This helps us better understand the glaucomatous process when combined with the results of other multicentered studies3-5 that find IOP lowering can retard the progression of glaucoma at various stages of the disease process.
The critical question is how to apply this information in clinical practice and policy making. Kass et al and Gordon et al find that medical treatment halves the development of the earliest detectable glaucoma damage given our current techniques. At 60 months, only 4.4% of treated patients compared with . . . [Full Text of this Article]
Alan L. Robin, MD;
Kevin D. Frick, PhD;
Joanne Katz, PhD;
Donald Budenz, MD;
James M. Tielsch, PhD
Baltimore, Md
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Unsupervised Machine Learning with Independent Component Analysis to Identify Areas of Progression in Glaucomatous Visual Fields
Sample et al.
IOVS 2005;46:3684-3692.
ABSTRACT
| FULL TEXT
Incorporating the Results of the Ocular Hypertension Treatment Study Into Clinical Practice
Kass et al.
Arch Ophthalmol 2005;123:1021-1022.
FULL TEXT
Screening for Primary Open-Angle Glaucoma in the Primary Care Setting: An Update for the US Preventive Services Task Force
Fleming et al.
Ann Fam Med 2005;3:167-170.
ABSTRACT
| FULL TEXT
|
